2011
Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis
Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, Williams J, Hiatt P, Gibson RL, Spencer T, Orenstein D, Chatfield BA, Froh DK, Burns JL, Rosenfeld M, Ramsey BW, Investigators F. Comparative Efficacy and Safety of 4 Randomized Regimens to Treat Early Pseudomonas aeruginosa Infection in Children With Cystic Fibrosis. JAMA Pediatrics 2011, 165: 847-856. PMID: 21893650, PMCID: PMC3991697, DOI: 10.1001/archpediatrics.2011.136.Peer-Reviewed Original ResearchConceptsPseudomonas aeruginosa infectionCulture-based therapyCulture-based groupsCystic fibrosisAeruginosa infectionEarly Pseudomonas aeruginosa infectionTobramycin inhalation solutionPrimary end pointRate of exacerbationsExacerbation rateIntravenous antibioticsOral ciprofloxacinOral placeboAntibiotic regimensPulmonary exacerbationsAdverse eventsTreat analysisMulticenter trialAntipseudomonal treatmentInhalation solutionOdds ratioComparative efficacyPlaceboEnd pointFibrosis
2009
Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,
Treggiari MM, Rosenfeld M, Mayer-Hamblett N, Retsch-Bogart G, Gibson RL, Williams J, Emerson J, Kronmal RA, Ramsey BW, Group E. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: Rationale and design of the EPIC clinical trial and observational study,. Contemporary Clinical Trials 2009, 30: 256-268. PMID: 19470318, PMCID: PMC2783320, DOI: 10.1016/j.cct.2009.01.003.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAnti-Bacterial AgentsChildChild, PreschoolCiprofloxacinCohort StudiesCystic FibrosisDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationFemaleHumansInfantLongitudinal StudiesMalePseudomonas aeruginosaPseudomonas InfectionsRisk FactorsTobramycinTreatment OutcomeConceptsEarly Pa infectionYoung CF patientsRespiratory culturesRisk factorsCystic fibrosisCohort studyPA infectionClinical trialsObservational studyCF patientsEarly CF lung diseaseProgressive obstructive pulmonary diseaseProportion of patientsClinical efficacy dataObstructive pulmonary diseasePositive respiratory culturesPatients ages 1Longitudinal cohort studyCF lung diseaseChronic endobronchial infectionInfection control programPa acquisitionPA-negative patientsOral ciprofloxacinOral placebo